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background: The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) demonstrated a heightened risk of stroke associated with 
Darbepoetin alfa (DA) use. Although stroke was not a primary endpoint, this finding raised significant patient safety concerns. The Reduction of 
Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial randomized 2,278 patients with systolic heart failure and mild to moderate anemia 
(hemoglobin (Hb) level, 9-12 g/dL) to DA or placebo to raise Hb. Despite sustained increases in Hb, there were no significant differences in any 
outcomes, but the stroke rate was higher with DA.
Methods: Within RED-HF 816 patients had diabetes and eGFR <60 mL/min/1.73m2 and met inclusion criteria for TREAT. We examined event rates 
in this group and, for a more reliable estimation of the effect of DA on cardiovascular and renal events, we conducted an analysis combining TREAT-
like patients in RED-HF with the 4,038 TREAT patients.
results: The combined group (n=4,854) confirms the neutral findings of TREAT on death and all cardiorenal events and reconfirms the increased 
stroke risk.
conclusions: The independent trial RED-HF provides confirmation of the neutral efficacy and increased risk of stroke associated with DA seen in 
TREAT.
Event Rates and Hazard Ratios Associated with Darbepoetin Alfa Use
Endpoint
DA
N=2416
Placebo
N=2438
Overall
N=4854
TREAT-like RED-HF
N=816
TREAT
N=4038
Event Number (%) Hazard Ratio (95% CI)
CV Composite 854 (35.3) 830 (34.0) 1.02 (0.92-1.12) 0.91 (0.76-1.09) 1.05 (0.94-1.17)
Death 587 (24.3) 587 (24.1) 1.00 (0.89-1.12) 0.89 (0.73-1.09) 1.05 (0.92-1.21)
Heart Failure 334 (13.8) 355 (14.6) 0.93 (0.80-1.08) 1.00 (0.79-1.28) 0.89 (0.74-1.08)
MI 151 (6.3) 166 (6.8) 0.89 (0.71-1.11) 0.68 (0.41-1.12) 0.96 (0.75-1.22)
Stroke 123 (5.1) 63 (2.6) 1.94 (1.43-2.63) 2.07 (0.98-4.38) 1.92 (1.38-2.68)
Renal Composite 837 (34.6) 822 (33.7) 1.01 (0.92-1.11) 0.87 (0.71-1.06) 1.06 (0.95-1.19)
ESRD 350 (14.5) 349 (14.3) 0.98 (0.85-1.14) 0.57 (0.28-1.17) 1.02 (0.87-1.18)
